ICER presents alternative pricing models for remdesivir as a treatment for COVID-19

ICER

1 May 2020 - Models present prices according to two different paradigms: “cost recovery” approach and traditional cost-effectiveness analysis.

The Institute for Clinical and Economic Review (ICER) today released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. 

Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, representing an estimate based on peer-reviewed methods of calculating the minimum costs of production for a course of therapy; and 2) traditional cost-effectiveness analyses looking at the incremental health benefits and costs within the health system. 

Preliminary data available on remdesivir allows for initial non-peer-reviewed pricing analyses at this time, and the models will be used to track and evaluate any potential future treatments for COVID-19.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Pricing , COVID-19